(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 October 2005 (06.10.2005)

PCT

(10) International Publication Number
WO 2005/091956 A2

(51) International Patent Classification: Not classified

(21) International Application Number:
PCT/US2005/006942

(22) International Filing Date: 3 March 2005 (03.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/550,868	5 March 2004 (05.03.2004)	US
60/585,980	7 July 2004 (07.07.2004)	US
60/646,095	21 January 2005 (21.01.2005)	US

(71) Applicant *(for all designated States except US)*: **Chiron Corporation** [US/US]; Intellectual Property - R440, P. O. Box 8097, Emeryville, CA 94662 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **CAO, Ying** [CN/US]; c/o Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608 (US). **DENIS-MIZE, Kimberly** [US/US]; c/o Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608 (US). **WILSON, Susan, E.** [GB/US]; c/o Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608 (US).


(74) Agents: **HARBIN, Alisa** et al.; Chiron Corporation, Intellectual Property - R440, P. O. Box 8097, Emeryville, CA 94662 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH,

[Continued on next page]

(54) Title: IN VITRO TEST SYSTEM FOR PREDICTING PATIENT TOLERABILITY OF THERAPEUTIC AGENTS



(57) Abstract: Methods for predicting patient tolerability to therapeutic agents, such as cytokines, lymphokines and immunotoxins, are disclosed. The methods utilize an in vitro model of vascular leak syndrome (VLS) to assess the effect of the agent in question on the permeability of large proteins across confluent monolayers of endothelial cells (EC).

WO 2005/091956 A2

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.